Andere Kunden interessierten sich auch für
![Prostate Cancer]( "Prostate Cancer")
Prostate Cancer111,99 €![Molecular Imaging II]( "Molecular Imaging II")
Molecular Imaging II229,99 €![Anticipating and Assessing Health Care Technology, Volume 2]( "Anticipating and Assessing Health Care Technology, Volume 2")
Anticipating and Assessing Health Care Technology, Volume 2147,99 €![Management of rare adult tumours]( "Management of rare adult tumours")
Management of rare adult tumours150,99 €![Molecular Imaging I]( "Molecular Imaging I")
Molecular Imaging I231,99 €![Fundamentals of Nuclear Pharmacy]( "Fundamentals of Nuclear Pharmacy")
Fundamentals of Nuclear Pharmacy81,99 €![Radiation Toxicity: A Practical Medical Guide]( "Radiation Toxicity: A Practical Medical Guide")
Radiation Toxicity: A Practical Medical Guide116,99 €
from combining radiation with a molecular targeted agent - namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
From the reviews:
"Major advances in radiation oncology ... are reviewed in this book. ... Resident, attending and practicing radiation oncologists are the intended audience. The authors are respected radiation oncology practitioners and researchers. ... This excellent account of the major recent advances in radiation oncology is well written and edited. ... It is useful for both practicing and in-training radiation oncologists." (Jyoti Mayadev, Doody's Review Service, December, 2008)
"Major advances in radiation oncology ... are reviewed in this book. ... Resident, attending and practicing radiation oncologists are the intended audience. The authors are respected radiation oncology practitioners and researchers. ... This excellent account of the major recent advances in radiation oncology is well written and edited. ... It is useful for both practicing and in-training radiation oncologists." (Jyoti Mayadev, Doody's Review Service, December, 2008)